Background
==========

In recent years cancer patients have been able to survive for longer than those diagnosed a few decades ago. We usually report five-year relative survival rates after diagnosis in the annual reports of regional cancer registries in Japan. However, these survival estimates may be pessimistic for cancer survivors, because many patients with unfavourable prognosis die shortly after diagnosis.

Conditional survival analysis is a method to estimate survival rates, with the pre-condition of having already survived a certain length of time. The figures have been reported in the US and other countries, and can provide cancer survivors, their families and oncologists with more relevant information \[[@B1]-[@B11]\].

In 2007, the Basic Plan to Promote Cancer Control Programs of Japan was approved, following the establishment of the Cancer Control ACT of Japan in 2006. Improvement of cancer care support and information services is one of the specific goals of this program \[[@B12]\]. Longstanding population-based cancer registry data can provide this type of useful information to cancer survivors. We used cancer patient data from the Osaka Cancer Registry, which has a long history and covers the largest population in Japan, to report conditional survival in patients with six major cancers by age group and stage at diagnosis.

Methods
=======

Data sources
------------

We analysed 38,439 cases diagnosed with first, primary, invasive malignant tumour of the following cancers: stomach (International Classification of Diseases, 10^th^ revision code \[[@B13]\]: C16), colorectal (C18-C20), lung (C33, C34), breast (C50, female only) and prostate (C61) from 1990--2004. They were followed up between 2000 and 2004 in Osaka, Japan, from the Osaka Cancer Registry database. We limited the data to patients who were diagnosed at age 15 to 69 years. Patients over 70 years of age at diagnosis were excluded from the analyses as long-term survival estimates are unstable for older age groups. In the Osaka Cancer Registry, we followed patients up using the death certificate database for residents in Osaka prefecture. However, if patients had moved outside the Osaka Prefecture after diagnosis the death certificate database would be unable to capture their details. In these cases resident registries were used to follow the patients up. Residents in Osaka-city (30% of total population of Osaka prefecture) were not followed-up using residence registries before 1993, so patients who lived in Osaka-city were excluded from the analysis. Cases diagnosed from 1990 to 1999 were followed up for 10 years after diagnosis, whereas follow-up was limited to 5 years for those diagnosed from 2000 to 2004 (Figure [1](#F1){ref-type="fig"}).
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Statistical analysis
--------------------

First, we estimated ten-year relative survival using the Osaka Cancer Registry data by sex, age group (15--49, 50--59 and 60--69 years old) and stage at diagnosis (localised, regional and distant metastasis). Relative survival is a ratio of the observed survival (overall survival) and the survival that would have been expected if the cancer patient had only experienced the normal (background) mortality of the general population in which they live \[[@B14]\]. In this study we estimated relative survival using the maximum likelihood method developed by Esteve et al. \[[@B15]\] and the publicly available Stata programme *strel*\[[@B16]\]. We derived the expected survival from complete (single-year-of-age) national population life tables by sex \[[@B17]\]. We used conventional 10-year relative survival estimating based on data from patients who were diagnosed from1995-1999 and were followed-up over 10 years (dashed line in Figure [1](#F1){ref-type="fig"}). However, calculation of long-term survival using the conventional method is outdated. We therefore used period analysis to derive more up-to-date long-term survival using data from recently followed-up cancer patients \[[@B18]\]. In this study, we used data from cancer patients who were diagnosed from 1990--2004 and followed-up between 2000 and 2004 (solid black line, in Figure [1](#F1){ref-type="fig"}).

Second, we calculated conditional five-year survival for patients who survived for 0 to 5 years after diagnosis using ten-year cumulative relative survival. To estimate the five-year conditional survival of patients who survived x years, the (x + 5)-year cumulative survival rates is divided by the x-year cumulative survival. In the other words, conditional five-year survival is five-year survival of the patients who are alive several years after diagnosis \[[@B2],[@B10]\].

Third, for missing stage cases, we used the multiple imputation approach \[[@B19]\]. We examined the characteristics of patients with missing stage before multiple imputation, then we assumed the mechanism of missingness as Missing At Random. The relative survival of the ten completed data sets contained the imputed value of stage for cases with missing information (6.4-17.1%). The imputation model was a multinomial logistic regression including follow-up time, vital status, period of diagnosis, age at diagnosis, and interactions between follow-up time and other factors. Rubin's rules were applied to estimate relative survival and standard errors combining the ten completed data sets. All statistical analyses were performed using the standard statistical package Stata Ver. 12.1 \[[@B20]\].

Results
=======

The characteristics of patients we analysed are shown in Table [1](#T1){ref-type="table"}. Conditional five-year survival for all stage patients under the age of 70 by site of cancer is shown in Figure [2](#F2){ref-type="fig"}. For stomach cancer, the five-year relative survival for all cases is 60% at diagnosis. 77% of patients who survived one year (one-year survivor) can survive an additional five years. Conditional five-year survival at two years after diagnosis was 87%. Conditional five-year survival at five years after diagnosis was 97%. This means 97% of the stomach cancer patients who survived for more than five years can survive another five years. Colorectal and lung cancer showed similar results to stomach cancer patients. However, conditional five-year survival for liver cancer did not increase after any period post diagnosis. Conditional survival for breast and prostate cancer patients was stable at around 85-90%.

###### 

Characteristic of cancer patients for selected sites of cancer in Osaka, Japan in 1990--2004

                                   **Stomach**   **Colon/rectum**   **Liver**   **Lung**   **Breast**   **Prostate**                                       
  ------------------------------- ------------- ------------------ ----------- ---------- ------------ -------------- ------ ------- ------ ------- ------ -------
  **Total**                           10278           100.0           8411       100.0        4800         100.0       6397   100.0   7229   100.0   1324   100.0
  **Age**                                                                                                                                                      
    15-49                             1266             12.3            897        10.7        296           6.2        549     8.6    2591   35.8     6      0.5
    50-59                             3442             33.5           2830        33.6        1344          28.0       2024   31.6    2752   38.1    214    16.2
    60-69                             5570             54.2           4684        55.7        3160          65.8       3824   59.8    1886   26.1    1104   83.4
  **Stage (before imputation)**                                                                                                                            
    Localised                         4863             50.7           3568        45.3        2897          72.8       1426   23.8    3747   57.3    785    65.4
    Regional                          2758             28.8           2577        32.7        663           16.7       2167   36.2    2439   37.3    175    14.6
    Distant                           1972             20.6           1728        21.9        421           10.6       2397   40.0    350     5.4    241    20.1
    Missing                            685            (6.7)            538       (6.4)        819          (17.1)      407    (6.4)   693    (9.6)   123    (9.3)
  **Stage (after imputation)**                                                                                                                             
    Localised                         5202             50.6           3817        45.4        3436          71.6       1511   23.6    4139   57.3    865    65.3
    Regional                          2960             28.8           2757        32.8        818           17.0       2304   36.0    2701   37.4    196    14.8
    Distant                           2116             20.6           1837        21.8        546           11.4       2582   40.4    389     5.4    263    19.9
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By age group
------------

Results by age group are shown in Figure [3](#F3){ref-type="fig"}. Most cancer sites showed similar results among the different age groups. In liver cancer patients, conditional survival increased in the young group (under the age of 50). In prostate cancer patients, the older age group (60--69 years old) showed better conditional survival than the younger age group (50--59 years old).
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By stage
--------

Figures for conditional survival by stage at diagnosis were different for different cancers (Figure [4](#F4){ref-type="fig"}). In all except liver cancer patients, the figures for conditional survival for localised patients were high at around 90%. In stomach, colorectal and lung cancer patients, even the regional and distant metastasis cases showed high five-year survival for five-year survivors. In liver cancer patients, even localised cases showed low conditional five-year survival. In breast and prostate cancer patients, conditional five-year survival for each stage was stable.
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Discussion
==========

Conditional five-year relative survival improved successively with each additional year that patients lived following diagnosis for stomach, colorectal and lung cancer. This pattern was also similar to the regional or distant metastasis cases. Breast and prostate cancer showed different trends; conditional five-year survival was stable at a higher level. Liver cancer did not show any increase in conditional five-year survival.

Stomach and colorectal cancer
-----------------------------

For stomach and colorectal cancer patients who survived more than five years after diagnosis, conditional five-year survival was close to 100%. This means that those who survived five years would have the same survival probability as the general population, i.e. they can be considered as 'cured' of cancer. Although it is difficult to define clinical 'cure' at the individual level, we can define the concept of 'cure' at population level \[[@B21],[@B22]\]. Conditional five-year survival for localised cases was stable at more than 90%. Those for regional or distant metastasis increased according to the number of years since diagnosis. Even late stage patients who survive a few years have a chance of living another five years.

Lung cancer
-----------

Conditional survival in lung cancer patients increased according to the additional years after diagnosis. However, the figures were lower than those for stomach and colorectal cancer. This was because lung cancer patients have a higher risk of death due to complications related to cancer or cancer risk (smoking), such as ischemic heart disease.

Breast and prostate cancer
--------------------------

Conditional five-year survival rates for all cases of both breast and prostate cancer were around 80-90%, due to the higher proportion of localised patients in all cases. Conditional five-year survival for localised prostate cancer patients slightly decreased five years after diagnosis. This could be partly explained by the recurrence or progression of tumours during long-term follow-up. For these cancers, we need to follow-up patients for a longer period.

Liver cancer
------------

Conditional survival for liver cancer was much lower than for other cancers at any stage or age after several years. Even in localised patients, conditional five-year survival was less than 40% after five years. This is probably because many liver cancer patients experienced a recurrence of cancer, or died from liver cirrhosis or liver failure related to the hepatitis B or C virus.

Effect of age and stage at diagnosis
------------------------------------

Trends in conditional survival by age group were quite similar except for liver and prostate cancer. For most cancers, age did not significantly affect conditional survival. In the case of liver cancer, conditional survival for young patients (15--49 years old) was higher than for old patients (60--69 years old) after several years. This could be explained by the fact that the old patients had been exposed to hepatitis viruses for long time; as a result, they tended to develop liver cirrhosis and liver failure more than young patients. Conditional survival of young prostate cancer patients (50--59 years old) was lower than old patients (60--69 years old). This is probably because young patients are diagnosed at a more advanced stage than old patients (the proportion of distant metastasis was 35.2% in 50-59-year-old patients and 28.3% in 60-69-year-old patients).

The conditional survival curve was different by stage; stage at diagnosis was an important prognostic factor. Conditional survival for localised patients was stable at 85-95%, while for regional and distant metastasis patients it increased after several years of diagnosis.

Trends in conditional survival for breast and colorectal cancer patients in Osaka were similar to other countries (shown in Additional file [1](#S1){ref-type="supplementary-material"}: Figures S1-S4 from Australia \[[@B2],[@B6]\], US \[[@B8]\], Canada \[[@B5],[@B11]\] and European countries \[[@B3],[@B9]\]). Conditional survival for prostate cancer at all stages in Osaka was lower than other countries. This is due to the low proportion of localised patients in Japan compared to other countries. Conditional survival of stomach cancer for all stage and localised in Osaka was higher than in Australia \[[@B2]\]. Stomach cancer patients in Osaka were diagnosed at an earlier stage than in Australia (e.g. 51% patients diagnosed at localised stage in Osaka, 28% in Australia). In addition, approximately half of the stomach cancer patients in Japan were diagnosed at T1 (UICC TNM classification) \[[@B23]\]. Therefore we can estimate a higher proportion of T1 in localised patients in Osaka than in Australia. Higher conditional survival for localised patients can be partly explained by differences in tumour. This may be due to stomach cancer screening programmes \[[@B24]\] and wide use of endoscopy in clinical settings in Japan. Conditional survival of localised lung cancer in Osaka was higher than in other countries. This could be explained by differences in tumour size and histology \[[@B25],[@B26]\]. Conditional survival for liver cancer patients in Canada increased some years after diagnosis \[[@B11]\], while in Osaka it was stable at low survival. This can be explained by the differences in etiological factor among these countries. In the US and Canada, prevalence of hepatitis B or C viruses in liver cancer cases was lower than in Japan \[[@B27]\]. Liver cancer patients in Japan might have greater likelihood of liver failure or hepatitis-related cirrhosis than those in the US and Canada.

Conditional five-year survival for stomach and colorectal cancer patients who were alive five years after diagnosis was about 100%; this means those patients have similar survival probability to the general population. Therefore those patients can be considered as 'cured'. For other sites of cancer, further long-term follow-up time may be needed to estimate 'cured' time.

Conditional survival is an important statistic for planning long-term life after diagnosis, not only for cancer patients and their families, but also patients with other diseases. However, a population-based disease registry system, such as the population-based cancer registry, is essential to estimate this type of statistic.

Conclusion
==========

Conditional five-year survival is a relevant figure for long-term cancer survivors in Japan. It is important for population-based cancer registries to provide figures which cancer patients and oncologists really need.
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